58 related articles for article (PubMed ID: 7567946)
1. p53 gene status in endometrial carcinomas showing diffuse positivity for p53 protein by immunohistochemical analysis.
Ambros RA; Ross JS; Kallakury BV; Malfetano J; Kim Y; Hwang J; Breese K; Figge J
Mod Pathol; 1995 May; 8(4):441-5. PubMed ID: 7567946
[TBL] [Abstract][Full Text] [Related]
2. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.
O'Malley FP; Vnencak-Jones CL; Dupont WD; Parl F; Manning S; Page DL
Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120
[TBL] [Abstract][Full Text] [Related]
3. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
4. p53 mutations and histological type of invasive breast carcinoma.
Marchetti A; Buttitta F; Pellegrini S; Campani D; Diella F; Cecchetti D; Callahan R; Bistocchi M
Cancer Res; 1993 Oct; 53(19):4665-9. PubMed ID: 8402644
[TBL] [Abstract][Full Text] [Related]
5. Genetic alterations at the splice junction of p53 gene in human hepatocellular carcinoma.
Hsu HC; Huang AM; Lai PL; Chien WM; Peng SY; Lin SW
Hepatology; 1994 Jan; 19(1):122-8. PubMed ID: 7903951
[TBL] [Abstract][Full Text] [Related]
6. A frequent alteration of p53 gene in carcinoma in adenoma of colon.
Ohue M; Tomita N; Monden T; Fujita M; Fukunaga M; Takami K; Yana I; Ohnishi T; Enomoto T; Inoue M
Cancer Res; 1994 Sep; 54(17):4798-804. PubMed ID: 8062281
[TBL] [Abstract][Full Text] [Related]
7. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma.
Jia L; Liu Y; Yi X; Miron A; Crum CP; Kong B; Zheng W
Clin Cancer Res; 2008 Apr; 14(8):2263-9. PubMed ID: 18369088
[TBL] [Abstract][Full Text] [Related]
8. Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas.
Nikaido T; Li SF; Shiozawa T; Fujii S
Cancer; 1996 Sep; 78(6):1248-53. PubMed ID: 8826947
[TBL] [Abstract][Full Text] [Related]
9. Infrequent p53 gene mutations and lack of p53 protein expression in clear cell sarcoma of the kidney: immunohistochemical study and mutation analysis of p53 in renal tumors of unfavorable prognosis.
Hsueh C; Wang H; Gonzalez-Crussi F; Lin JN; Hung IJ; Yang CP; Jiang TH
Mod Pathol; 2002 Jun; 15(6):606-10. PubMed ID: 12065773
[TBL] [Abstract][Full Text] [Related]
10. The role of p53 mutations in bilateral breast carcinoma.
Ackerman J; Baunoch DA; Gimotty P; George J; Lane MA; Dawson PJ
Mod Pathol; 1995 Apr; 8(3):244-8. PubMed ID: 7617647
[TBL] [Abstract][Full Text] [Related]
11. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
12. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
[TBL] [Abstract][Full Text] [Related]
13. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
[TBL] [Abstract][Full Text] [Related]
14. Absence of p53 gene mutation and infrequent overexpression of p53 protein in hepatoblastoma.
Chen TC; Hsieh LL; Kuo TT
J Pathol; 1995 Jul; 176(3):243-7. PubMed ID: 7674087
[TBL] [Abstract][Full Text] [Related]
15. p53 alterations in chemically induced hamster cheek-pouch lesions.
Gimenez-Conti IB; LaBate M; Liu F; Osterndorff E
Mol Carcinog; 1996 Aug; 16(4):197-202. PubMed ID: 8784462
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
Temmim L; Baker H; Sinowatz F
Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837
[TBL] [Abstract][Full Text] [Related]
17. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
18. Expression of immunoreactivity and genetic mutation in eosinophilic and ciliated metaplastic changes of endometrial glandular and stromal breakdown: cytodiagnostic implications.
Shimizu K; Norimatsu Y; Kobayashi TK; Sakurai M; Ogura S; Yoshizawa A; Miyamoto T; Miyake Y; Aratake Y; Sakaguchi T; Ohno E
Ann Diagn Pathol; 2009 Apr; 13(2):89-95. PubMed ID: 19302956
[TBL] [Abstract][Full Text] [Related]
19. Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas.
Varley JM; Brammar WJ; Lane DP; Swallow JE; Dolan C; Walker RA
Oncogene; 1991 Mar; 6(3):413-21. PubMed ID: 2011397
[TBL] [Abstract][Full Text] [Related]
20. [P53-status in primary ovarian carcinomas, ovarian metastases of neoplasms in other sites and benign ovarian tumors: predictive value in comparison to histopathological parameters].
Casper F; Weikel W; Schaffrath M; Kuner RP; Hoffmann G; Pollow B; Pollow K
Zentralbl Gynakol; 2000; 122(3):153-9. PubMed ID: 10756599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
